The Dreaden Lab uses molecular engineering to impart augmented, amplified, or non-natural function to tumor therapies and immunotherapies. The overall goal of our research is to engineer molecular and nanoscale tools that can (i) improve our understanding of fundamental tumor biology and (ii) simultaneously serve as cancer therapies that are more tissue-exclusive and patient-personalized. The lab is housed on the Emory SOM campus and currently focuses on three main application areas: optically-triggered immunotherapies, combination therapies for pediatric cancers, and nanoscale cancer vaccines. Our work aims to translate these technologies into the clinic and beyond.
Dr. Dreaden holds joint faculty appointments in the Coulter Department of Biomedical Engineering and the Department of Pediatrics at Georgia Tech and Emory's School of Medicine. Prior to joining the faculty, he was a postdoctoral fellow at the Koch Institute for Integrative Cancer Research at MIT, where his research aimed to develop polymer-based technologies for nucleic acid and rational combination cancer therapies. His PhD training at Georgia Tech focused on the development of multivalent and photo-activated targeted cancer therapies based on nanoscale colloids. He is a native Atlantan and a life-long Braves fan.